{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:59:12Z","timestamp":1785473952814,"version":"3.56.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sepsis-induced cardiomyopathy (SICM) is an important cardiovascular complication of infection and sepsis, particularly in patients with type 2 diabetes mellitus (T2DM). Whether antecedent glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower SICM risk remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective active-comparator cohort study using the TriNetX United States federated electronic health record network from 1 January 2010, to 30 November 2025. Adults with T2DM and documented infection were classified according to antecedent GLP-1 RA or dipeptidyl peptidase-4 inhibitor (DPP-4i) exposure before the index infection date and matched 1:1 by propensity score. The primary outcome was 1-year EHR-ascertained SICM or SICM-related cardiac dysfunction, defined using diagnostic codes for acute pulmonary edema, heart failure, cardiogenic shock, or cardiomyopathy, or objective cardiac dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 189,156 eligible patients, propensity-score matching yielded 62,267 patients in each group. Over 1 year, EHR-ascertained SICM or SICM-related cardiac dysfunction occurred in 2,503 patients (4.0%) in the GLP-1 RA group and 3,059 patients (4.9%) in the DPP-4i group (HR 0.82, 95% CI 0.78\u20130.87; P &amp;lt; 0.001; E-value 1.7). GLP-1 RA use was also associated with lower risks of surrogate cardiac dysfunction (HR 0.70, 95% CI 0.64\u20130.76), systolic SICM (HR 0.85, 95% CI 0.77\u20130.93), diastolic SICM (HR 0.88, 95% CI 0.81\u20130.95), hyperdynamic SICM (HR 0.82, 95% CI 0.71\u20130.95), new-onset heart failure (HR 0.85, 95% CI 0.80\u20130.89), and all-cause mortality (HR 0.64, 95% CI 0.60\u20130.68), but not right ventricular dysfunction SICM. Negative control outcomes showed null associations, and landmark analyses were consistent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this United States real-world active-comparator cohort study, antecedent GLP-1 RA exposure was associated with a lower 1-year risk of EHR-ascertained SICM or SICM-related cardiac dysfunction compared with antecedent DPP-4i exposure. These findings were consistent across sensitivity analyses and support further prospective investigation into the relationship between antecedent GLP-1 RA exposure and cardiovascular vulnerability after infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1877392","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:24:20Z","timestamp":1785471860000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Antecedent glucagon-like peptide-1 receptor agonist use and risk of sepsis-induced cardiomyopathy in type 2 diabetes: a United States real-world active-comparator cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Jheng-Yan","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Nutrition, Chi Mei Medical Center","place":["Tainan, Taiwan"]},{"name":"Department of Public Health, College of Medicine, National Cheng Kung University","place":["Tainan, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng-Wei","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chi Mei Hospital","place":["Chiali, Tainan, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Chi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Chi Mei Medical Center","place":["Tainan, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Yuan","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Hepatogastroenterology, Department of Internal Medicine, Chi Mei Medical Centre","place":["Tainan, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Min","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center","place":["Tainan, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1093\/eurheartj\/ehaf340","article-title":"Sepsis-induced cardiomyopathy","volume":"46","author":"Aissaoui","year":"2025","journal-title":"Eur. Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/CCM.0000000000002851","article-title":"Septic cardiomyopathy","volume":"46","author":"Beesley","year":"2018","journal-title":"Crit. Care Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"997578","DOI":"10.3389\/fimmu.2022.997578","article-title":"GLP-1 receptor agonist as a modulator of innate immunity","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00592-021-01728-4","article-title":"Type 2 diabetes mellitus and sepsis: state of the art, certainties and missing evidence","volume":"58","author":"Costantini","year":"2021","journal-title":"Acta Diabetol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J. Anaesth."},{"key":"B6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"B7","doi-asserted-by":"publisher","first-page":"114390","DOI":"10.1016\/j.intimp.2025.114390","article-title":"GLP-1 as a regulator of sepsis outcomes: insights into cellular metabolism, inflammation, and therapeutic potential","volume":"152","author":"Fan","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e004040","DOI":"10.1161\/CIRCOUTCOMES.117.004040","article-title":"Myocardial injury in patients with sepsis and its association with long-term outcome","volume":"11","author":"Frencken","year":"2018","journal-title":"Circ. Cardiovasc Qual. Outcomes"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e2013","DOI":"10.1016\/S2214-109X(25)00356-0","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2021: a systematic analysis","volume":"13","year":"2025","journal-title":"Lancet Glob. Health"},{"key":"B10","doi-asserted-by":"publisher","first-page":"106645","DOI":"10.1016\/j.jinf.2025.106645","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of infections: a systematic review and meta-analysis","volume":"91","author":"Han","year":"2025","journal-title":"J. Infect."},{"key":"B11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4266\/acc.2021.00234","article-title":"Sepsis-induced cardiomyopathy is associated with higher mortality rates in patients with sepsis","volume":"36","author":"Hanumanthu","year":"2021","journal-title":"Acute Crit. Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1177\/08850666231180526","article-title":"Prevalence and prognosis of sepsis-induced cardiomyopathy: a systematic review and meta-analysis","volume":"38","author":"Hasegawa","year":"2023","journal-title":"J. Intensive Care Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"Jama"},{"key":"B14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (Glucagon-Like Peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Helmst\u00e4dter","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3390\/antiox10081175","article-title":"GLP-1 analog liraglutide improves vascular function in polymicrobial sepsis by reduction of oxidative stress and inflammation","volume":"10","author":"Helmst\u00e4dter","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/thorax-2024-221906","article-title":"Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data","volume":"80","author":"Henney","year":"2024","journal-title":"Thorax"},{"key":"B17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41569-020-00492-2","article-title":"Pathophysiology of sepsis-induced cardiomyopathy","volume":"18","author":"Hollenberg","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1007\/s00125-024-06102-x","article-title":"Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment","volume":"67","author":"Holt","year":"2024","journal-title":"Diabetologia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13098-022-00803-2","article-title":"Impact of diabetes mellitus on outcomes of patients with sepsis: an updated systematic review and meta-analysis","volume":"14","author":"Jiang","year":"2022","journal-title":"Diabetol. Metab. Syndr."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/crd.0000000000000970","article-title":"The cardiovascular benefits of glucagon-like Peptide-1 (GLP-1) receptor agonists","author":"Kallash","year":"2025","journal-title":"Cardiol. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00210-010-0559-9","article-title":"GLP-1 signaling preserves cardiac function in endotoxemic fischer 344 and DPP4-deficient rats","volume":"382","author":"Ku","year":"2010","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"112001","DOI":"10.1016\/j.diabres.2025.112001","article-title":"The impact of diabetes on sepsis-induced cardiomyopathy","volume":"220","author":"Lai","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B23","doi-asserted-by":"publisher","first-page":"110523","DOI":"10.1016\/j.biopha.2020.110523","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-\u03baB and MAPK pathways via GLP-1R","volume":"130","author":"Li","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.1038\/s41467-025-59616-2","article-title":"Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study","volume":"16","author":"Lin","year":"2025","journal-title":"Nat. Commun."},{"key":"B25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13613-022-01089-3","article-title":"Association of sepsis-induced cardiomyopathy and mortality: a systematic review and meta-analysis","volume":"12","author":"Lin","year":"2022","journal-title":"Ann. Intensive Care"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3389\/fimmu.2017.01021","article-title":"Sepsis-induced cardiomyopathy: mechanisms and treatments","volume":"8","author":"Liu","year":"2017","journal-title":"Front. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMra2403213","article-title":"Sepsis and septic shock","volume":"391","author":"Meyer","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/medsci13040237","article-title":"Subclinical myocardial dysfunction in type 2 diabetes mellitus: insights from left ventricular diastolic function and global longitudinal strain assessment","volume":"13","author":"Nghiem","year":"2025","journal-title":"Med. Sci. (Basel)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40779-022-00410-2","article-title":"DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits","volume":"9","author":"Razavi","year":"2022","journal-title":"Mil. Med. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.chest.2020.12.016","article-title":"Impact of right ventricular dysfunction on short-term and long-term mortality in sepsis: a meta-analysis of 1,373 patients","volume":"159","author":"Vallabhajosyula","year":"2021","journal-title":"Chest"},{"key":"B31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-Value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann. Intern Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.amjmed.2013.06.029","article-title":"Elevated cardiac troponin T levels in critically ill patients with sepsis","volume":"126","author":"Vasile","year":"2013","journal-title":"Am. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"112324","DOI":"10.1016\/j.diabres.2025.112324","article-title":"GLP-1 receptor agonists and hospitalization due to infections in patients with type 2 diabetes: a nationwide cohort study","volume":"226","author":"Wang","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B34","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41569-023-00877-z","article-title":"Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention","volume":"20","author":"Wong","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e043373","DOI":"10.1161\/JAHA.125.043373","article-title":"Nonsteroidal Versus steroidal mineralocorticoid receptor antagonists in heart failure: real-world evidence from a multicenter cohort study","volume":"14","author":"Wu","year":"","journal-title":"J. Am. Heart Assoc."},{"key":"B37","doi-asserted-by":"publisher","first-page":"112918","DOI":"10.1016\/j.diabres.2025.112918","article-title":"Clinical outcomes of SGLT2 inhibitors among patients with MASLD and T2DM","volume":"229","author":"Wu","year":"","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B38","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s13054-025-05685-0","article-title":"Association between SGLT2 inhibitor use and risk of sepsis-induced cardiomyopathy in patients with type 2 diabetes: a propensity-matched cohort study","volume":"29","author":"Wu","year":"","journal-title":"Crit. Care"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1652863","DOI":"10.3389\/fcvm.2026.1652863","article-title":"Real-world effectiveness of SGLT2 inhibitors in patients with HF and ESKD: a multicenter cohort study","volume":"13","author":"Wu","year":"2026","journal-title":"Front. Cardiovasc Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13098-023-01118-6","article-title":"The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials","volume":"15","author":"Yu","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3892\/mmr.2015.4724","article-title":"Glucagon-like peptide-1 protects cardiomyocytes from advanced oxidation protein product-induced apoptosis via the PI3K\/Akt\/Bad signaling pathway","volume":"13","author":"Zhang","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"109252","DOI":"10.1016\/j.cbi.2020.109252","article-title":"GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1\u03b2-induced metabolic disturbance and mitochondrial dysfunction","volume":"332","author":"Zhang","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"B43","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1877392\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:24:23Z","timestamp":1785471863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1877392\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":43,"alternative-id":["10.3389\/fphar.2026.1877392"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1877392","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1877392"}}